Innate Pharma (IPHA) Debt to Equity (2017 - 2019)

Innate Pharma (IPHA) has disclosed Debt to Equity for 3 consecutive years, with $0.09 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Debt to Equity rose 197.44% year-over-year to $0.09, compared with a TTM value of $0.09 through Dec 2019, up 197.44%, and an annual FY2019 reading of $0.09, up 197.44% over the prior year.
  • Debt to Equity was $0.09 for Q4 2019 at Innate Pharma, up from $0.03 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.09 in Q4 2019 and bottomed at $0.03 in Q4 2018.
  • Average Debt to Equity over 3 years is $0.06, with a median of $0.07 recorded in 2017.
  • The sharpest move saw Debt to Equity crashed 57.56% in 2018, then surged 197.44% in 2019.
  • Year by year, Debt to Equity stood at $0.07 in 2017, then plummeted by 57.56% to $0.03 in 2018, then surged by 197.44% to $0.09 in 2019.
  • Business Quant data shows Debt to Equity for IPHA at $0.09 in Q4 2019, $0.03 in Q4 2018, and $0.07 in Q4 2017.